Company news
Abcellera Biologics Inc. (NASDAQ:ABCL) news
Every Abcellera Biologics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
August 13, 2026
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Se...
August 10, 2026
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on ...
August 7, 2026
AbCellera Biologics : Q2 2026 Business Update Presentation
August 5, 2026
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
July 29, 2026
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
July 7, 2026
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
July 6, 2026
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
June 5, 2026
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
May 11, 2026
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
May 7, 2026
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
April 20, 2026
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
April 1, 2026
AbCellera Reports Full Year 2025 Business Results
February 24, 2026
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
February 11, 2026
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
January 22, 2026
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Sym...
January 12, 2026
AbCellera and Bruker Reach Global Settlement of Patent Litigation
December 18, 2025
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
December 8, 2025
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
November 10, 2025
AbCellera Reports Q3 2025 Business Results
November 6, 2025
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
October 7, 2025
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
September 29, 2025
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
September 10, 2025
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
August 27, 2025
AbCellera to Participate at Upcoming Investor Conferences in September
August 12, 2025
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
August 7, 2025
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
July 7, 2025
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
May 30, 2025
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menop...
May 14, 2025
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
May 12, 2025
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
May 9, 2025
AbCellera Reports Q1 2025 Business Results
May 8, 2025
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
April 29, 2025
AbCellera to Participate at Upcoming Investor Conferences in May and June
April 8, 2025
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
April 3, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
March 25, 2025
AbCellera Reports Full Year 2024 Business Results
February 27, 2025
AbCellera to Participate at Upcoming Investor Conferences in March
February 11, 2025
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
January 21, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
January 13, 2025
AbCellera to Present at Upcoming Investor Conferences in December and January
November 21, 2024
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
November 7, 2024
AbCellera Reports Q3 2024 Business Results
November 4, 2024
AbCellera to Present at Upcoming Investor Conferences in November 2024
October 22, 2024
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
October 4, 2024
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
September 26, 2024
AbCellera to Present at Upcoming Investor Conferences in September
August 29, 2024
AbCellera Reports Q2 2024 Business Results
August 6, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
July 31, 2024
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
June 25, 2024